Recent clinical trials indicate that the severity of diabetic neuropathy is correlated with the level of patient glycemic control. In the current study, hyperglycemia induces apoptotic changes in dorsal root ganglion neurons and Schwann cells in vivo both in streptozotocin-treated diabetic rats and in rats made acutely hyperglycemic with infused glucose. Typical apoptotic nuclear and cytoplasmic changes are observed. In addition mitochondrial changes recently reported to occur as part of the apoptotic cascade, such as ballooning of mitochondria and disruption of the internal cristae, are seen in diabetic dorsal root ganglion neurons and Schwann cells. Similar changes have been reported in neurons in the presence of oxidative stress. In order to study the neurotoxic effects of high glucose we developed an in vitro model using rat dorsal root ganglion neurons. In dorsal root ganglion cultured in defined medium, addition of moderate glucose levels results in neurite degeneration and apoptosis. These changes are coupled with activation of caspase-3, dependent on the concentration of glucose. The apoptotic changes observed in vitro are similar to those observed in vivo. In contrast, addition of IGF-I, even at physiological concentrations, prevents activation of caspase-3 and neuronal apoptosis in vitro. We suggest that oxidative stress may promote the mitochondrial changes in diabetic animals and lead to activation of programmed cell death caspase pathways. These results imply a new pathogenetic mechanism for diabetic sensory neuropathy.
INTRODUCTION
Diabetic neuropathy is the most common cause of peripheral neuropathy in the Western world and occurs in approximately 50% of diabetic patients over time (Pirart, 1978; Dyck et al., 1991) . While the Diabetes Control and Complications Trial has implicated hyperglycemia in the development of diabetic neuropathy (DCCT Research Group, 1993; The Diabetes Control and Complications Trial Research Group, 1995) , the pathogenesis of this common complication of diabetes remains unknown (Feldman et al., 1997a; Greene et al., 1997) . Multiple etiologies have been proposed, including altered polyol metabolism, superoxide radical formation, protein glycation, vascular insufficiency, and blunted nitric oxide production (Feldman et al., 1997a; Greene et al., 1997) . Therapeutic strategies based on these potential etiologies have been used in clinical trials for over 10 years with variable results (Feldman et al., 1997a; Greene et al., 1997) .
We are interested in the defects in neuronal metabolism produced by high glucose as a first step toward understanding the events that underlie the development of diabetic neuropathy. In our work, we simulate both the in vitro and the in vivo stressors that the peripheral nervous system is subjected to in the diabetic state (Matthews & Feldman, 1996; Matthews et al., 1997; Singleton et al., 1996a; Feldman et al., 1997a) . When we expose human SH-SY5Y neuroblastoma cells to high glucose or mannitol, conditions designed to simulate diabetes mellitus, we find that these cells undergo programmed cell death (PCD) (Matthews et al., 1995 (Matthews et al., , 1997 Matthews & Feldman, 1996; Singleton et al., 1996b; Cheng & Feldman, 1998; Russell et al., 1998) . These data lead us to speculate that neuronal PCD may contribute to the development of diabetic neuropathy.
